Page 4 - Nasdaq Mack News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK – Get Rating)’s stock price passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $5.46 and traded as high as $5.89. Merrimack Pharmaceuticals shares last traded at $5.68, with a volume of 7,552 shares. Separately, StockNews.com started coverage on Merrimack Pharmaceuticals […]

Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK – Get Rating) Director Noah G. Levy bought 20,938 shares of the company’s stock in a transaction dated Tuesday, June 14th. The stock was purchased at an average cost of $5.17 per share, for a total transaction of $108,249.46. Following the completion of the acquisition, the director now owns 1,010,515 shares […]

StockNews.com assumed coverage on shares of Merrimack Pharmaceuticals (NASDAQ:MACK – Get Rating) in a note issued to investors on Monday. The firm set a “sell” rating on the biopharmaceutical company’s stock. Shares of MACK opened at $4.95 on Monday. The firm’s 50-day moving average price is $5.71 and its 200-day moving average price is $5.30. […]

StockNews.com initiated coverage on shares of Merrimack Pharmaceuticals (NASDAQ:MACK – Get Rating) in a research report issued to clients and investors on Sunday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock. Shares of NASDAQ MACK opened at $5.49 on Friday. The business has a fifty day simple moving average of $5.82 and […]

StockNews.com started coverage on shares of Merrimack Pharmaceuticals (NASDAQ:MACK – Get Rating) in a report released on Saturday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock. NASDAQ:MACK opened at $5.25 on Friday. The company has a market capitalization of $70.40 million, a price-to-earnings ratio of -37.50 and a beta of 1.68. Merrimack […]